| 李 蕾,阚立东,王玉云,姚 毅,肖 雷.康柏西普治疗不同OCT分型视网膜静脉阻塞性黄斑水肿的临床疗效及对视力、CRT的影响[J].现代生物医学进展英文版,2024,(12):2269-2273. |
| 康柏西普治疗不同OCT分型视网膜静脉阻塞性黄斑水肿的临床疗效及对视力、CRT的影响 |
| Clinical Effect of Conbercept in the Treatment of Different OCT Types of Retinal Vein Occlusion Induced Macular Edema and the Influence on Vision and CRT |
| Received:November 23, 2023 Revised:December 17, 2023 |
| DOI：10.13241/j.cnki.pmb.2024.12.012 |
| 中文关键词: 康柏西普 光学相干断层扫描 视网膜静脉阻塞 黄斑水肿 |
| 英文关键词: Conbercept Optical coherence tomography Retinal vein occlusion Macular edema |
| 基金项目:安徽省卫生健康委科研项目（AHWJ2021a047） |
|
| Hits: 225 |
| Download times: 171 |
| 中文摘要: |
| 摘要 目的：观察康柏西普治疗不同光学相干断层扫描（OCT）分型视网膜静脉阻塞（RVO）性黄斑水肿（ME）的临床疗效及对视力、CRT的影响。方法：选取2020年1月~2023年6月我院收治的RVO性ME患者60例，根据OCT分型将其分为弥漫性视网膜增厚（DRT）组（n=24）、囊样水肿（CME）组（n=21）、浆液性视网膜脱离（SRD）组（n=15）。所有患者均给予康柏西普治疗，比较三组患者治疗后6个月的临床疗效，治疗前后的视力水平、黄斑中心视网膜厚度（CRT），并统计三组治疗后6个月内并发症的发生情况。结果：DRT组患者临床疗效的总有效率为91.67%，显著高于CME组（61.90%）与SRD组（66.67%）（P<0.05）。治疗后3个月和6个月三组患者的logMAR BCVA、CRT水平均呈降低趋势，均低于治疗前（P＜0.05），且DRT组患者水平logMAR BCVA、CRT水平均低于CME组与SRD组（P＜0.05），CME组、SRD组logMAR BCVA、CRT比较差异不显著（P＞0.05）。治疗后6个月三组并发症发生率比较差异不显著（P>0.05）。结论：康柏西普治疗RVO性ME患者的疗效肯定，有助于改善视力及CRT水平，安全性较高，其中DRT患者治疗效果较其他OCT分型患者更佳，值得推荐。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the clinical efficacy of conbercept in the treatment of different optical coherence tomography (OCT) types of retinal vein occlusion (RVO) induced macular edema (ME), and the influence on vision and central retinal thickness (CRT). Methods: A total of 60 patients with RVO induced ME who were admitted to the hospital from January 2020 to June 2023 were selected, and divided into the diffuse retinal thickening (DRT) group (n=24), the cystoid macular edema (CME) group (n=21) and the serous retinal detachment (SRD) group (n=15) according to OCT classification. All patients were treated with conbercept. Clinical efficacy 6 months after treatment, visual acuity and CRT before and after treatment were compared among the 3 groups. The incidence rates of complications within 6 months of treatment were calculated. Results: The total clinical response rate in the DRT group (91.67%) was significantly higher than that in the CME group(61.90%) and the SRD group (66.67%)(P<0.05). 3 months and 6 months after treatment, logMAR BCVA and CRT in the 3 groups were lower than those before treatment(P<0.05). The logMAR BCVA and CRT in the DRT group were lower than those in the CME group and the SRD group(P<0.05), but there was no statistically significant difference between the CME group and the SRD group(P>0.05). There was no statistically significant difference in the total incidence of complications among the 3 groups 6 months after treatment (P>0.05). Conclusion: Conbercept is effective in the treatment of patients with RVO induced ME. It is conducive to improving vision and CRT, with high safety. The therapeutic effect on DRT is better than other OCT types. |
|
View Full Text
View/Add Comment Download reader |
| Close |
